The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1528
ISSUE 1528
August 28, 2017
Issue 1528
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Drugs for Asthma
August 28, 2017 (Issue: 1528)
The goal of asthma treatment is to control symptoms
and prevent exacerbations. Management of acute
exacerbations of asthma is not discussed here.
- JL McCracken et al. Diagnosis and management of asthma in adults: a review. JAMA 2017; 318:279.
- KR Jat and A Khairwa. Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. Pulm Pharmacol Ther 2013; 26:239.
- JP Parsons et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med 2013; 187:1016.
- MA Rank et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 131:724.
- JK Mukker et al. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids. J Pharm Sci 2016; 105:2509.
- HW Kelly et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367:904.
- AL Fuhlbrigge and HW Kelly. Inhaled corticosteroids in children: effects on bone mineral density and growth. Lancet Respir Med 2014; 2:487.
- PM O’Byrne et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011; 183:589.
- DA Stempel et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med 2016; 374: 1822.
- SP Peters et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. N Engl J Med 2016; 375:850.
- DA Stempel et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. N Engl J Med 2016; 375:840.
- D Radovanovic et al. The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscip Respir Med 2017; 12:12.
- KM Kew and K Dahri. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev 2016; 1:CD011721.
- LA Lee et al. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respir Med 2015; 109:54.
- TE Albertson et al. Muscarinic antagonists in early stage clinical development for the treatment of asthma. Expert Opin Investig Drugs 2017; 26:35.
- HA Kerstjens et al. Tiotropium for the treatment of asthma: a drug safety evaluation. Expert Opin Drug Saf 2016; 15:1115.
- G Calapai et al. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology 2014; 94:60.
- Global Initiative for Asthma. Global strategy for asthma management and prevention, 2017. Available at: http://ginasthma.org. Accessed August 17, 2017.
- SK Medrek et al. Fungal sensitization is associated with increased risk of life-threatening asthma. J Allergy Clin Immunol Pract 2017; 5:1025.
- KF Chung et al. International ERS/ATS guidelines on definition, evaluation, and treatment of severe asthma. Eur Respir J 2014; 43:343.
- MA Calderón et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011; 127:30.
- GJ Rodrigo et al. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139:28.
- NA Hanania et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154:573.
- BE Chipps et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol 2017; 139:1431.
- L Cox et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 2011; 128:210.
- Mepolizumab (Nucala) for severe eosinophilic asthma. Med Lett Drugs Ther 2016; 58:11.
- Reslizumab (Cinqair) for severe eosinophilic asthma. Med Lett Drugs Ther 2016; 58:81.
- HG Ortega et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198.
- HG Ortega et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophilic thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4:549.
- EH Bel et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189.
- M Castro et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3:355.
- ER Bleecker et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388:2115.
- JM FitzGerald et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388:2128.
- P Nair et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376:2448.
- M Pretolani et al. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations. J Allergy Clin Immunol 2017; 139:1176.
- A Trivedi et al. Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma. Lancet Respir Med 2016; 4:585.
- PG Gibson et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017 July 4 (epub).
- V Bougault et al. Airway hyperresponsiveness in elite swimmers: is it a transient phenomenon? J Allergy Clin Immunol 2011; 127:892.
- JA Namazy and M Schatz. Pharmacological difficulties in the treatment of asthma in pregnant women. Expert Rev Clin Pharmacol 2017; 10:285.
- NA Hodyl et al. Fetal glucocorticoid-regulated pathways are not affected by inhaled corticosteroid use for asthma during pregnancy. Am J Respir Crit Care Med 2011; 183:716.
- B Cossette et al. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Ann Allergy Asthma Immunol 2014; 112:459.
- RA Charlton et al. Safety of fluticasone propionate prescribed for asthma during pregnancy: a UK population-based cohort study. J Allergy Clin Immunol Pract 2015; 3:772.
- L Blais et al. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol 2009; 124:1229.
- LN Bakhireva et al. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol 2007; 119:618.
- B Cossette et al. Impact of maternal use of asthma-controller therapy on perinatal outcomes. Thorax 2013; 68:724.
- FDA Drug Safety Communication: FDA review fi nds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). December 20, 2017. Available at: www.fda.gov. Accessed March 20, 2018.
- Benralizumab (Fasenra) for severe eosinophilic asthma. Med Lett Drugs Ther 2018; 60:33.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1528
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.